The cell surface glycoprotein MUC18MCAM/CD146 was originally defined as a marker of melanoma progression and has been suspected to be directly linked to the metastatic process of this malignancy. In order to address this question, 2 MCAM negative human melanoma cell lines, SK-2 and XP44RO(Mel), were transfected with MCAM-encoding cDNA. Surface MCAM expression on SK-2 and XP44RO(Mel) transfectants was similar to that observed in naturally occurring MCAM positive human melanoma cells and transfectants demonstrated MCAM-dependent increase in homotypic adhesion in vitro. The growth behavior of 7 MCAM transfectants and their respective vector controls was evaluated in SCID mice. Tumor size at 4-5 weeks after s.c. implantation was highly variable, but did not correlate with MCAM expression. Despite massive primary tumor formation at the injection site, no spontaneous metastasis was observed with any of the investigated MCAM transfectants. The influence of MCAM expression on lung metastases formation in an experimental metastasis assay was system dependent, converting only XP44RO(Mel) transfectants into metastatic cells, although increased homotypic adhesion, leading to formation of tumor cell clusters, was observed with transfectants of both cell lines in vitro. Our findings indicate that MCAM expression of human melanoma cells has an influence on later stages of the metastatic process only, namely, extravasation and establishment of new foci of growth, but is per se not sufficient for this process.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1002/(sici)1097-0215(19990611)81:6<951::aid-ijc18>3.0.co;2-v | DOI Listing |
JMIR Form Res
January 2025
Department of Medical Informatics, Amsterdam UMC - University of Amsterdam, Amsterdam, Netherlands.
Background: The prognosis for patients with several types of cancer has substantially improved following the introduction of immune checkpoint inhibitors, a novel type of immunotherapy. However, patients may experience symptoms both from the cancer itself and from the medication. A prototype of the eHealth tool Cancer Patients Better Life Experience (CAPABLE) was developed to facilitate symptom management, aimed at patients with melanoma and renal cell carcinoma treated with immunotherapy.
View Article and Find Full Text PDFLasers Med Sci
January 2025
Department of Ophthalmology, Ankara University School of Medicine, Ankara, Turkey.
The aim of the study was todescribe the clinical features, optical coherence tomography (OCT) and fundus autofluorescence (FAF) imaging in patients with choroidal and retinal tumors. Ninety eyes of 89 patients with treatment-naive macular, midperipheral, and juxtapapillary choroidal and retinal tumors were retrospectively included in the study. All patients underwent a complete ophthalmic examination, B-mode ultrasonography, OCT, and FAF imaging.
View Article and Find Full Text PDFFront Immunol
January 2025
The Lautenberg Center for Immunology and Cancer Research, The Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem, Israel.
Alternative splicing (AS) is a mechanism that generates translational diversity within a genome. Equally important is the dynamic adaptability of the splicing machinery, which can give preference to one isoform over others encoded by a single gene. These isoform preferences change in response to the cell's state and function.
View Article and Find Full Text PDFCureus
December 2024
Neurological Surgery, Hospital Central do Funchal, Funchal, PRT.
Metastases to the pituitary gland are a rare finding, with breast and lung being the most common metastases in this anatomical region. Pituitary melanoma metastases reports are thus sparse, and both diagnosis and treatment are challenging. We present the case of a 66-year-old woman with pituitary melanoma metastasis who presented with symptoms of anterior pituitary dysfunction and headache.
View Article and Find Full Text PDFJ Transl Med
January 2025
Department of Plastic and Reconstructive Surgery, Zhongshan Hospital, Fudan University, 180 Fenglin Road, Shanghai, 200032, People's Republic of China.
Cutaneous melanoma is one of the most aggressive skin cancers originating from skin pigment cells. Patients with advanced melanoma suffer a poor prognosis and generally cannot benefit well from surgical resection and chemo/target therapy due to metastasis and drug resistance. Thus, adoptive cell therapy (ACT), employing immune cells with specific tumor-recognizing receptors, has emerged as a promising therapeutic approach to display on-tumor toxicity.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!